A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity

Neurotoxicity Syndromes Clinical Trial

Official title: A Pilot Study of Dextromethorphan for the Prevention and Treatment of Methotrexate Neurotoxicity

Status Terminated

Clinical Trial Summary

The purposes of this study are to find out whether dextromethorphan can prevent the short or long-term neurologic side effects of methotrexate, and whether dextromethorphan can improve symptoms of short-term neurologic side effects if they do occur.

Clinical Trial Description

We believe that we are beginning to understand the biological cause of the neurotoxicity that happens after treatment with methotrexate. Dextromethorphan, an ingredient in common cough medicines, may be able to prevent and/or treat this neurotoxicity. We have given dextromethorphan to a small group of patients who developed severe neurologic side effects after methotrexate. All had a complete recovery within one day. ;

Study Design

Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neurotoxicity Syndromes

• NCT number: NCT00176553
• Study type: Interventional
• Source: Rutgers, The State University of New Jersey
• Status: Terminated
• Phase: N/A
• Start date: March 2003
• Completion date: May 2007